08 Feb Potential Benefit of Aspirin in Colon Cancer Prevention
These results add to emerging data that suggest a potential benefit of aspirin toward primary or secondary cancer chemoprevention....
These results add to emerging data that suggest a potential benefit of aspirin toward primary or secondary cancer chemoprevention....
Mr. Nguyen[/caption]
David-Dan Nguyen
Research Fellow | Center for Surgery and Public Health, Brigham and Women's Hospital
MPH (Health Policy) Student | Harvard T.H. Chan School of Public Health
Medical Student | McGill University
MedicalResearch.com: What is the background for this study?
Response: The COVID-19 pandemic has forced hospitals to delay the definitive treatment of cancers via surgery or radiation therapy. While previous evidence has shown that delaying the treatment of low-risk prostate cancer is not associated with worse outcomes, treatment delays for intermediate-risk and high-risk prostate cancer are more controversial. As such, we sought to determine if delays for these disease states negatively impacted oncological outcomes.
Try to understand what they’re going through
Dr. Hoskins[/caption]
Kent Hoskins, MD
Eileen Lindsay Heidrick Professor in Oncology
Division of Hematology/Oncology
University of Illinois at Chicago
Director of Cancer Genetics
Co-Leader, Breast Cancer Research Group
University of Illinois Cancer Center
MedicalResearch.com: What is the background for this study?
Response: The racial disparity in breast cancer mortality emerged in the US in the late 1980s in the wake of widespread implementation of mammography screening and the development of successful systemic adjuvant therapies for early breast cancer. Unfortunately, more than three decades later, Black women in the US still have a 40% higher mortality rate from breast cancer compared with non-Hispanic White women despite similar disease incidence. Health disparities research has primarily focused on the fact that Black women have a higher incidence of the aggressive triple-negative subtype, and that they are more likely to present with more advanced stages of disease. As important as those factors are, in recent years our group and others reported that Black women with hormone receptor-positive breast cancer have worse survival than non-Hispanic white women even after adjustment for stage at diagnosis and treatment. Since nearly 2/3 of breast cancers in Black women are hormone receptor-positive, this is a significant contributor to the overall mortality disparity. Importantly, these studies also suggested that Black women disproportionately develop biologically aggressive forms of hormone-dependent breast cancer, which is typically considered a more favorable disease subtype.
Using data on more than 70,000 patients from the SEER registry that is linked to data from Genomic Health Laboratory, which provides the Oncotype DX recurrence score (the most commonly ordered prognostic/predictive multi-gene expression assay for early breast cancer), we set out to address three questions:
1) is there evidence of disproportionately aggressive tumor biology among Black women with hormone receptor (HR)-positive breast cancer, as reflected in the Oncotype DX recurrence score?
2) Is there a racial survival disparity even among patients with early stage, axillary node-negative tumors with comparable recurrence scores on the Oncotype assay? and
3) Is there is a difference in the prognostic accuracy of the Oncotype assay between Black and non-Hispanic white patients, since there was limited representation of Black women in the development and validation of the Oncotype assay and other prognostic/predictive assays?
Dr. Bishehsari[/caption]
Faraz Bishehsari, MD, PhD
Associate Professor of Medicine and Graduate College
Director of the Translational Gastroenterology Unit
Division of Digestive Diseases
Rush University Medical Center
MedicalResearch.com: What is the background for this study?
Response: This study builds on recent population based studies where opium use was found to be possible risk factor for pancreatic cancer. Although opium use is not a common recreational habit in the United States, opioid use has been rising remarkably over the past decade. In fact, opioid misuse and overdose have evolved into a public health crisis here with increasing opioid prescription use and abuse over the past decade.
Dr. Boursi[/caption]
Ben Boursi MD
Senior Physician in the Gastrointestinal Cancer Department at Sheba Medical Center
School of Medicine, Sackler Faculty of Medicine
Tel Aviv University
Tel Aviv, Israel
MedicalResearch.com: What is the background for this study? What conditions have fecal matter transplants been previously studied in (ie c. diff)?
Response: “Many melanoma patients do not respond to immunotherapy and even among responders, many eventually progress. Extensive research has been conducted in order to overcome resistance to immunotherapy and modulation of the gut microbiota, is one of the promising leads. The gut microbiome has been shown to influence response to immunotherapy in preclinical mouse models and observational patient cohorts. Currently FMT is being used for the treatment of C. Difficile that is resistant to antibiotics, but it is also being evaluated as a treatment option for other disease states such as inflammatory bowel disease and obesity.”
Dr. Marshall[/caption]
Deborah C. Marshall, MD
New York University School of Medicine
New York, New York
MedicalResearch.com: What is the background for this study? What are the main findings?
Response: Tarras ES, Marshall DC, Rosenzweig K, Korenstein D, Chimonas S. Trends in Industry Payments to Medical Oncologists in the United States Since the Inception of the Open Payments Program, 2014 to 2019. JAMA Oncol. Published online December 30, 2020. doi:10.1001/jamaoncol.2020.6591
MedicalResearch.com: What should readers take away from your report?
Response: Overall, though, there has not been a dramatic shift in these interactions after the inception of Open Payments.
Dr. Van Haren[/caption]
Robert Van Haren, MD, MSPH
College of Medicine
University of Cincinnati
MedicalResearch.com: What is the background for this study?
Response: The COVID-19 pandemic has impacted all areas of society including the field of oncology. This study evaluated the impact of COVID-19 on lung cancer screening. Screening with low-dose computed tomography (LDCT) scans are important because they reduce lung cancer mortality by at least 20%. Our lung cancer screening program was closed in March 2020 due to COVID 19 and reopened again in June 2020. We cancelled over 800 LDCTs during that time period.
Dr. Brody[/caption]
Joshua Brody MD
Director, Lymphoma Immunotherapy Program
Icahn School of Medicine at Mount Sinai
Hess Center for Science and Medicine
New York, New York 10029
MedicalResearch.com: What is the background for this study?
Response: Cancer Immunotherapies target "antigens" on the surface of cells.
-CAR-T cells targets antigens e.g. CD19
-Bispecific antibodies target antigens e.g. CD20
-Anti-PD1 antibodies awaken T cells that target antigens on e.g. MHC-I
Cancer Immunotherapies frequently fail because a small percent of tumor cells simply lack the antigen and cause cancer relapse ('Antigen Escape')
Dr. Blum[/caption]
Joanne L. Blum, MD, PhD, FACP
Texas Oncology and Director
Hereditary Cancer Risk Program
Baylor University Medical Center
MedicalResearch.com: What is the background for this study? Would you briefly describe the POLARIS study?
Response: POLARIS is an ongoing prospective, real-world, non-interventional study in patients with HR+/HER2-ABC receiving palboiclib plus endocrine therapy with a targeted enrollment of 1500 patients at 110 sites in the United States and Canada.
MedicalResearch.com: What are the main findings?
William Wood, MD
Associate Professor of Medicine, Division of Hematology
UNC School of Medicine
MedicalResearch.com: What is the background for this study? What are the main findings?
Response: In the earliest days of the COVID-19 pandemic, there were concerns that individuals with cancer, and especially those with hematologic malignancies, could be at higher risk for adverse outcomes following COVID-19 infection than the general population. For this reason the ASH Research Collaborative developed a voluntary data collection registry in which providers or sites caring for patients with hematologic malignancies and COVID-19 infection provided de-identified data via an online data collection platform.
We believe that our findings – that 20% of patients with blood cancers who had COVID-19 infection died, including 33% of those who required hospital or ICU level-care – indicate that patients with blood cancers are a medically vulnerable group when it comes to COVID-19. The risk of dying was highest in patients who were older, had more severe infection, opted to forego more intensive treatment, and/or had poorer prognosis before their COVID-19 infection, as determined by their treating clinicians
Dr. Corina Dutcus MD
Vice President of Clinical Research
Oncology Business Group
Eisai
MedicalResearch.com: What is the background for this study? Would you briefly explain how lenvatinib works? Is it used for any other malignancies, ex. thyroid cancer?
Response: LENVIMA (lenvatinib), discovered and developed by Eisai, is an orally available multiple receptor tyrosine kinase inhibitor that inhibits the kinase activities of vascular endothelial growth factor (VEGF) receptors VEGFR1 (FLT1), VEGFR2 (KDR), and VEGFR3 (FLT4). LENVIMA inhibits other kinases that have been implicated in pathogenic angiogenesis, tumor growth, and cancer progression in addition to their normal cellular functions, including fibroblast growth factor (FGF) receptors FGFR1-4, the platelet derived growth factor receptor alpha (PDGFRα), KIT, and RET.
LENVIMA is approved in combination with everolimus for the treatment of patients with advanced renal cell carcinoma (RCC) following one prior anti-angiogenic therapy. The approved starting dose for LENVIMA is 18 mg daily. The objective of Study 218, a randomized, open-label, Phase 2 trial, was to assess whether the lower starting dose of LENVIMA (14 mg daily) in combination with everolimus (5 mg daily) would provide similar efficacy with an improved safety profile compared to the FDA-approved starting dose of LENVIMA (18 mg daily) plus everolimus (5 mg daily) in patients with advanced renal cell carcinoma (RCC) following prior treatment with an antiangiogenic therapy.
In the US, LENVIMA is also indicated for:
Dr. Bhardwaj[/caption]
Nina Bhardwaj MD PhD
Director of Immunotherapy
Tisch Cancer Institute
Icahn School of Medicine at Mt Sinai
Ward-Coleman Chair in Cancer Research
Professor of Hematology and Oncology
MedicalResearch.com: What is the background for this study?
Response: Neoantigens are novel antigens expressed by tumors as a result of somatic mutations or frame shift mutations. They can be very immunogenic and consequently they are being incorporated into cancer vaccine platforms. In most cases it is necessary to determine each patient’s individual mutations and customize their vaccine antigens accordingly. We sought to identify shared mutations in cancer antigens which are deficient in DNA repair mechanisms namely microsatellite unstable tumors. These tumors have mutations in genes that normally are responsible for ensuring that DNA is properly replicated. Because these genes encode proteins that ensure proper repair around micro-satellite areas (which contain short repeated sequences of DNA and are present in similar regions from one person’s genome to the next), when they are mutated, these regions may not be repaired. Consequently due to nucleotide deletions and insertions one gets frame shift mutations which result in new protein expression which can be shared across tumors, as has been observed for a few regions. We therefore did a comprehensive study of a subset of tumors to determine the breadth of shared frame shift mutations.
Dr. Pusztai[/caption]
Lajos Pusztai, M.D, D.Phil.
Professor of Medicine
Director, Breast Cancer Translational Research
Co-Director, Yale Cancer Center Genetics and Genomics Program
Yale Cancer Center
Yale School of Medicine
MedicalResearch.com: What is the background for this study? What are the main findings?
Response: In HER2-positive early stage (stage I-II) breast cancer, several different preoperative (also called neoadjuvant) chemotherapy options exist, each of these is associated with a different rate of complete eradication of cancer from the breast and lymph nodes (called pathologic complete response or pCR). Patients who experience pCR have excellent long term survival. The complete response rates range from 20% to 80%, the rates are higher with regimens that include several different chemotherapy drugs and dual HER2 blockade. Unfortunately, these highly effective multi-drug treatment regimens are also more toxic and more expensive. We also learned that patients who do not achieve pCR after preoperative therapy, have high rates of recurrence, but the recurrence rate can be improved by administering postoperative adjuvant therapy.
These two observations together, (1) different regimens with different toxicities and costs resulting in different pCR rates, and (2) existence of effective postoperative therapies for patients with residual cancer after preoperative therapy, sets the stage for combining various pre- and post-operative treatment strategies. Starting with a shorter, less toxic and less expensive neoadjuvant regimen would allow a substantial minority (20-45%) of patients who archive pCR to be spared of longer and more toxic regimens, whereas those with residual disease could receive the remaining part of the currently most effective regimens post-operatively as adjuvant therapy.
In this study we examined the cost effectiveness of different neoadjuvant followed by adjuvant treatment strategies from a healthcare payer perspective.
Dr. AlDubayan[/caption]
Saud H AlDubayan, M.D.
Instructor in Medicine, Harvard Medical School
Attending Physician, Division of Genetics,
Brigham and Women's Hospital
Computational Biologist, Department of Medical Oncology,
Dana-Farber Cancer Institute
Associate Scientist, The Broad Institute of MIT and Harvard
MedicalResearch.com: What is the background for this study? What are the main findings?
Response: The overall goal of this study was to assess the performance of the standard method currently used to detect germline (inhered) genetic variants in cancer patients and whether we could use recent advances in machine learning techniques to further improve the detection rate of clinically relevant genetic alterations.
To investigate this possibility, we performed a head to head comparison between the current gold-standard method for germline analysis that has been universally used in clinical and research laboratories and a new deep learning analysis approach using germline genetic data of thousands of patients with prostate cancer or melanoma. This analysis showed that across all different gene sets that were tested, the deep learning-based framework was able to identify additional cancer patients with clinically relevant germline variants that went undetected by the standard method. For example, several patients in our study also had germline variants that are associated with an increased risk of ovarian cancer, for which the surgical removal of the ovaries (at a certain age) is highly recommended. However, these genetic alterations were only identified by the proposed deep learning framework.
Dr. Estrada[/caption]
Sarah I. Estrada, M.D., FCAP
Laboratory Director
Affiliated Dermatology®
www.affderm.com
MedicalResearch.com: What is the background for this study? What are the main findings?
Response: As a dermatopathologist who makes diagnoses on lesions that may be melanoma, I’m faced with the reality that my accurate interpretation of biopsy tissue is key for the patient to be treated most effectively. Often histopathological evaluation is straightforward but not as often as I would like.
The study presented here offers a new test that can be used in conjunction with my evaluation to determine if a questionable lesion is in fact melanoma. The test was developed to take into account the gene expression of the lesion which may factor in characteristics that I cannot visually observe. The test was validated and has shown very promising accuracy metrics.
Dr. Bhardwaj[/caption]
Nina Bhardwaj MD, PhD
Professor of Medicine (Hematology and Medical Oncology) and Urology
Tisch Cancer Institute
Icahn School of Medicine at Mount Sinai
New York, NY
MedicalResearch.com: What is the background for this study? What types of cancer may be amenable to this vaccine?
Response: The goal was to determine if vaccine responses could be improved by increasing special white cell numbers, namely dendritic cells, which are key for jumpstarting an immune response.
MedicalResearch.com: What are the main findings?
Response: We found that the agent flt3-L mobilized these dendritic cells which help to improve the vaccine’s ability to prime the immune system.
Dr. Steiner[/caption]
Dave Steiner MD PhD
Clinical Research Scientist
Google Health, Palo Alto, California
MedicalResearch.com: What is the background for this study?
Response: For prostate cancer patients, the grading of cancer in prostate biopsies by pathologists is central to risk stratification and treatment decisions. However, the grading process can be subjective, often resulting in variability among pathologists. This variability can complicate diagnostic and treatment decisions. As an initial step towards addressing this problem, we and others in the field have recently developed artificial intelligence (AI) algorithms that perform on-par with expert pathologists for prostate cancer grading. Such algorithms have the potential to improve the quality and efficiency of prostate biopsy grading, but the impact of these algorithms when used by pathologists has not been well studied. In the current study, we developed and evaluated an AI-based assistant tool for use by pathologists while reviewing prostate biopsies.
Prof Jeffrey S Tobias, Prof Jayant S Vaidya, Prof Max Bulsara. and Prof Michael Baum[/caption]
Response: The findings of the large international randomised trial (TARGIT-A trial), published in the British Medical Journal (BMJ 2020;370:m2836), confirm the long-term effectiveness of Targeted Intraoperative Radiotherapy (TARGIT-IORT): a breast cancer treatment which is increasingly available throughout the world. For most women with early breast cancer, a single dose of targeted radiotherapy during surgery is just as effective as conventional radiotherapy, which requires several visits to hospital after surgery.
Conventional external beam radiotherapy (EBRT) is delivered from outside the body via a radiotherapy machine (linear accelerator), and consists of a daily treatment session (known as fractions) to the whole breast, over a period between three to six weeks. Each of these treatments is given over a few minutes, but requires 15 to 30 hospital visits, which could be a significant distance from where the patient lives.
TARGIT-IORT is delivered immediately after lumpectomy (tumour removal), via a small ball-shaped device placed inside the breast, directly where the cancer had been. The single-dose treatment lasts for around 20 to 30 minutes and replaces the need for extra hospital visits, benefiting both patient safety and well-being. The device used is called INTRABEAM.
More details are described on the BMJ and UCL webpages:
https://www.bmj.com/company/newsroom/single-dose-radiotherapy-as-good-as-conventional-radiotherapy-for-most-women-with-early-breast-cancer/
https://www.ucl.ac.uk/news/2020/aug/single-dose-radiotherapy-effective-treating-breast-cancer
https://blogs.bmj.com/bmj/2020/08/20/targeted-intraoperative-radiotherapy-for-early-breast-cancer-new-evidence/
Dr. Hussan[/caption]
Hisham Hussan, MD, FACG
The Ohio State University Wexner Medical Center
MedicalResearch.com: What is the background for this study?
Response: Early-onset colorectal cancer (i.e., CRC diagnosed before 50 years of age) is predicted to rise to 10.9% of all colon and 22.9% of all rectal cancers by 2030.
Some studies identified an association between early-onset CRC and obesity. By contrast, other studies found a similar body mass index (BMI) between adults with and without early-onset CRC. These conflicting findings are possibly due to weight loss from colorectal cancer that may obscure its relation to obesity.
Dr. Gade[/caption]
Kristine Gade, MD
Hematology/Oncology Fellow
UPMC Hillman Cancer Center
MedicalResearch.com: What is the background for this study? Would you briefly describe the “surprise question”?
Response: Via Oncology Pathways, a cancer care platform used by UPMC and other institutions across the country, asks physicians to answer the surprise question – “Would I be surprised if this patient died in the next 12 months?” – whenever a new treatment plan is implemented. This question has been widely adopted by many oncology and palliative care frameworks and has been shown to be modestly predictive of mortality in multiple studies. We know that advanced cancer patients have a high utilization of the emergency department, even near end of life. Our group wanted to see if we could use the results of the surprise question to easily and quickly communicate to emergency department providers the expected prognosis for our advanced cancer patients. First, we set out to assess the surprise question’s ability to predict survival among our UPMC Hillman Cancer Center patients with select stage IV cancer diagnoses.
Example of one type of squamous cell skin cancer: DermNetNZ image[/caption]Response: Cutaneous squamous cell carcinoma (cSCC) is the second most common skin cancer worldwide with still increasing incidence rates. Given these high incidence rates together with the associated health costs and possibility of fatal progression, it is extremely important to have accurate and complete data on the epidemiology of this disease. Nevertheless, national cancer registries in many countries do not routinely record cSCC cases and therefore currently known numbers are mainly based on incomplete data sources. Additionally, if cSCC cases are registered, this usually only concerns the first cSCC per patient while we know that, contrary to many other malignant neoplasms, patients may develop numerous cSCCs over time.
MedicalResearch.com: What are the main findings?
Response: In the present study, we analyzed Dutch nationwide data comprising about 145,000 patients with a first invasive cSCC diagnosis between the years 1989 and 2017. We found that the incidence rates of a first cSCC per patient almost tripled in male patients and increased about fivefold in female patients in this 30-year time period. Also, we had data on all cSCCs per patient for the year 2017 and could therefore compare this with the data on only the first cSCC per patient: incidence rates increased by 58% for men and 35% for women when multiple cSCCs were considered. In absolute numbers, this resulted in an increase of 45% in cSCC diagnoses in 2017. Lastly, we extended our analyses by predicting future cSCC incidence rates up to 2027. Given that no substantially effective measures are undertaken in the near future, current cSCC incidence rates will increase with 23% in males and 29% in females in the next decade.
Dr. Herbst[/caption]
Roy S. Herbst, M.D., Ph.D.
Ensign Professor of Medicine (Medical Oncology) and
Professor of Pharmacology
Chief of Medical Oncology
Yale Cancer Center and Smilow Cancer Hospital
Associate Cancer Center Director for Translational Research
Yale Cancer Center
MedicalResearch.com: What is the background for this study? How does osimertinib differ from prior versions of EGFR-TKI Inhibitors?
o ADAURA is a randomized, double-blinded, global and placebo-controlled Phase III trial in the adjuvant treatment of 682 patients with Stage IB, II, and IIIA EGFRm NSCLC following complete tumor resection and adjuvant chemotherapy as indicated. Patients were treated with osimertinib 80 mg once-daily oral tablets or placebo for three years or until disease recurrence. The primary endpoint is disease free survival (DFS) in Stage II and IIIA patients, and a key secondary endpoint is DFS in Stage IB, II and IIIA patients. Osimertinib is not currently approved in the adjuvant setting in any country.
o Osimertinib is a third-generation, irreversible EGFR-TKI with clinical activity against central nervous system metastases. The results of the Phase III ADAURA trial of osimertinib demonstrate for the first time in a global trial that an EGFR inhibitor can change the course of early-stage EGFR-mutated lung cancer for patients.
o ADAURA results were first presented in May during the American Society of Clinical Oncology ASCO20 Virtual Scientific Program.
Donna R. Cryer, JD[/caption]
Donna R. Cryer, JD
President & CEO of the Global Liver Institute
MedicalResearch.com: What is the background for this announcement? What is the mission of the GLI?
Response: Global Liver Institute 's (GLI) mission is to improve the impact of the liver community by promoting innovation, collaboration, and scaling optimal approaches to eradicating liver diseases. Our vision is for liver health to take its proper place on the global public health agenda consistent with its prevalence and impact. One of the ways we seek to fulfill that mission is through a #OctoberIs4Livers worldwide awareness campaign for the fight against liver cancer, reinforcing October as liver disease and liver cancer awareness month. Not only are we seeing a continuous rise of prevalence of liver cancers, but survival rates for liver cancers are also some of the lowest of any cancer.
Even more concerning is that the startling truth about the rise of liver cancer rates began before the COVID-19 pandemic. With the added burden of COVID-19, patients directly at risk from the virus may be diagnosed at a later stage due to delayed screening, and are getting sicker due to limitations on access to care during this pandemic. GLI is appealing to the US Congress to act now to secure the health and well-being of people living with liver disease and liver cancers during COVID-19. Funding is crucial to ensure federal agencies can restart and continue medical research, implement targeted prevention, and support awareness efforts for those impacted by liver disease as they are at increased risk for severe illness from COVID-19. [1]
Padma Sundar[/caption]
MedicalResearch.com Interview with:
Padma Sundar, Senior Vice President of Commercial , OncocyteTM
oncocyte.com
MedicalResearch.com: What is the background for this announcement? How common is Stage I-IIA non-squamous NSCLC?
DetermaRxTM is a treatment stratification test to identify patients with Stage I-IIA non-squamous NSCLC who may benefit from adjuvant chemotherapy.